Latisse

The U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. This once-daily prescribed treatment applied is to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator.


Latisse users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks.


The most common side effects after using Latisse solution are an itching sensation in the eyes and/or eye redness. This was reported in approximately


4% of patients. may experience other less common side effects which typically occur on the skin close to where Latisse is applied, or in the eyes. These include skin darkening, eye irritation, dryness of the eyes, and redness of the eyelids.


Latisse should not be used by individuals who have Glaucoma (increased interocular eye pressure) or are taking eye drops for eye pressure problems.